Member Info for researcher1

my prediction (guess) was for an RNS tomorrow, I think...

No1atlosing, I agree with Phil - this is a US listed company, a big difference to the usual US optimism...

did anyone keep a record of the predictions for day of RNS release?
and the latest SP predictions on RNS?

Don't give up just yet scrambler - let the US open for an hour, then we'll have some idea of the momentum...

no one on the board has issues with plain speaking gb, but there's no point in having a go at AN over a potential FDA delay caused by Covid. Anecdotally I've heard that FDA delays are not as bad as they first feared, so once the AIR is returned, who dare be out?

golferboy, it's FDA (NDA is a different matter) and second part of this year is five weeks away (a long wait?).
You also thought AN was evasive? I might accept 'frustrated' - he can't dictate when large pharma wake up to Parsortix - but the n again, the labs have only been open for two months.

thanks enteleon - yes I did say earlier in the thread how supportive FDA had been. Your point about live cell capture is of course a key USP and major competitive advantage, as well as incredibly beneficial to patients and surgeons alike. Great presentation from AN....

intriguing points BTHF - but most of those concerns (apart from machine breakage and integrity etc) would surely also apply to any drug the FDA considered? (so I'm implying, is beyond its jurisdiction...- they don't consider vaccine vials or hypos, for instance...

the FDA have been immensely supportive of Angle, if a little long-winded. Occasional sniping at the FDA, or worse, suspicion, is likely born of frustration at the length of time taken but, as miavoce says, is unfounded.

agreed Malachi. There are of course also malignancies that go undetected, and so Parsortix could potentially diagnose ahead of other tools in certain situations. Angle are not interested in this, but it does get me thinking....

sorry, have come to the thread quite late, but a useful addition might be to remind everyone of AN stating he had no concerns about Grail, indeed that if successful it could work very well as a prelude to Parsortix use. The comment demonstrates that Angle is not trying to move into mass screening/diagnostics at this point - huge, expensive trials would be required. Parsortix is however a key diagnostic tool once an at-risk patient is identified, and allows patient-specific treatments to be developed, as well as preventing biopsies on those who don't need it.

agreed K3 - and this is what AN is working toward. Hopefully post-FDA approval, with the SP North of £4, they can raise a large pot of cash to get multiple applications moving at rapid pace.

but not the one we thought - there's obviously a log-jam of the things....
we will need more clinics. Frankfurt?

whereas I hope we'll hear in the morning....

fair comment Jelenko, and I largely agree with your 'randomness' view, but yesterday's move seemed anticipatory, and there is market stress today (especially crypto) so I can see viable reasons.

traders disappointed the resubmission RNS hasn't dropped I expect miavoce. I confess I was expecting it too - or tomorrow...

just got another 5K myself Bojo. There are frequent small 'dips', but with recent research, Trinity guidance at 225p, and important news soon, it aint going far...

ha, I don't filter you BREX! happy to consider all voices here, even erratic ones! My TSLA target is 500 - I managed to get my last short at 889, but am now only in modest profit (a few K) but if it does hit that target, I will have considerably more to divert to Angle.

Indeed yes, they've bought two more machines! 3 X the research going on!

wynd, it took a breather intraday - remember there is clinic news and FDA submission likely in the coming days - an SP can ignore TA with such rockets ready to be lit - who on earth would sell at this point?? There may be some lull and drift whilst we wait for FDA, but imagine if the contracts keep on coming?